Summary
To understand comprehensive molecular mechanisms by which Autotaxin (ENPP2) mediates, we identified large-scale molecular changes responsible for aberrant expression of Autotaxin (ATX) on breast cancer cells by using DNA microarrays. Transcriptional over-expression of ENPP2 gene was endogenously silenced by using RNA interference technique, and then recapitulated corresponding molecular changes in MDA435 breast cancer cells. Application of nonparametric Wilcoxon statistical analyses (P<0.05) and the selection criteria of 2-fold differential gene expression change resulted in the identification of 368 genes including 133 up-regulated and 235 genes under-expressed in ENPP2-silencing MDA435 cells. Most of the functional categories of identified genes are associated with cellular metabolism, cytoskeleton organization, transcription regulation, signal transduction as well as cellular organization and biogenesis. Our data suggest that the molecular signature identified by the ENPP2-silencing methods may represent potential candidates that can explain the complicated characteristics of ATX and may serve as biomarkers, for the development of molecular-targeting therapy, in human breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57–70, 2000
Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, Schiffmann E: Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83: 3302–3306, 1996
Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524–2529, 1992
Clair T, Lee HY, Liotta LA, Stracke ML: Autotaxin is an exoenzyme possessing 5′-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 272: 996–1001, 1997
Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, Stracke ML: Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 271: 24408–24412, 1996
Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19: 241–247, 2000
Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61: 6938–6944, 2001
Clair T, Krutzsch HC, Liotta LA, Stracke ML: Nucleotide binding to autotaxin: Crosslinking of bound substrate followed by lysC digestion identifies two labeled peptides. Biochem Biophys Res Commun 236: 449–454, 1997
Stefan C, Stalmans W, Bollen M: Threonine autophosphorylation and nucleotidylation of the hepatic membrane protein PC-1. Eur J Biochem 241: 338–342, 1996
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227–233, 2002
Ferry G, Tellier E, Try A, Gres S, Naime I, Simon MF, Rodriguez M, Boucher J, Tack I, Gesta S, Chomarat P, Dieu M, Raes M, Galizzi JP, Valet P, Boutin JA, Saulnier-Blache JS: Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278: 18162–18169, 2003
Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63: 5446–5453, 2003
Yang Y, Mou L, Liu N, Tsao MS: Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21: 216–222, 1999
Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, Hoang-Vu C: Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109: 833–838, 2004
Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, Lee HY: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19: 603–608, 2000
Goetzl EJ, Dolezalova H, Kong Y, Zeng L: Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res 59: 4732–4737, 1999
Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6: R640–646, 2004
Chen M, O'Connor KL: Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 24: 5125–5130, 2005
Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582–591, 2003
Brindley DN: Lipid phosphate phosphatases and related proteins: Signaling functions in development, cell division, and cancer. J Cell Biochem 92: 900–912, 2004
Spiegel S, Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397–407, 2003
Lawler J: The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 12: 634–640, 2000
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noh, J.H., Ryu, S.Y., Eun, J.W. et al. Identification of large-scale molecular changes 1 of Autotaxin(ENPP2) knock-down by small interfering RNA in breast cancer cells. Mol Cell Biochem 288, 91–106 (2006). https://doi.org/10.1007/s11010-006-9124-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-006-9124-8